# Indoco Remedies (NSE: INDOCO) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/INDOCO · Pivot · prices to 21 Oct 2026

Indoco Remedies (NSE: INDOCO) closed at ₹230.30 on 21 Oct 2026. With a market capitalisation of ₹2,177 Cr, it ranks 1122nd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

Its return on equity was −10.1% in FY26. Over the past year the share price has fallen 17.9%. Its 52-week range is ₹162.19 (30 Mar 2026) to ₹291.00 (23 Oct 2025); the last close is 20.9% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹466 Cr (+8.7% year on year) and net profit ₹65 Cr, on a consolidated basis. Promoters held 58.86% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹230.30 |
| Market cap | ₹2,177 Cr |
| ROE | −10.1% (FY26) |
| ROCE | 1.2% (FY26) |
| Debt to equity | 1.1 |
| 52-week high | ₹291.00 (23 Oct 2025) |
| 52-week low | ₹162.19 (30 Mar 2026) |
| 1-year return | −17.9% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹466 Cr | +8.7% | ₹65 Cr | — | ₹7.09 |
| Q4 FY26 | ₹456 Cr | +18.8% | −₹24 Cr | — | −₹2.57 |
| Q3 FY26 | ₹434 Cr | +5.8% | −₹29 Cr | — | −₹3.20 |
| Q2 FY26 | ₹485 Cr | +12.0% | −₹9 Cr | — | −₹1.00 |
| Q1 FY26 | ₹429 Cr | −0.6% | −₹36 Cr | −2,097.3% | −₹3.94 |
| Q4 FY25 | ₹384 Cr | −14.6% | −₹41 Cr | −287.7% | −₹4.48 |
| Q3 FY25 | ₹411 Cr | −10.6% | −₹28 Cr | −282.5% | −₹3.08 |
| Q2 FY25 | ₹433 Cr | −10.2% | −₹10 Cr | −128.4% | −₹1.09 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹1,665 Cr | −₹78 Cr |
| FY24 | ₹1,817 Cr | ₹97 Cr |
| FY23 | ₹1,669 Cr | ₹142 Cr |
| FY22 | ₹1,541 Cr | ₹155 Cr |
| FY21 | ₹1,242 Cr | ₹93 Cr |
| FY20 | ₹1,107 Cr | ₹24 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 58.86%
- Foreign institutions: 1.27%
- Domestic institutions: 17.68%
- Non-institutions: 22.04%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Dishman Carbogen Amcis](https://app.pivotnow.in/stock/DCAL) | ₹146.03 | ₹2,290 Cr | 23.5 | — |
| [Vimta Labs](https://app.pivotnow.in/stock/VIMTALABS) | ₹505.00 | ₹2,256 Cr | 29 | — |
| [Medi Assist Healthcare Services](https://app.pivotnow.in/stock/MEDIASSIST) | ₹297.65 | ₹2,224 Cr | 24.5 | — |
| [Sai Parenterals](https://app.pivotnow.in/stock/SAIPARENT) | ₹482.75 | ₹2,133 Cr | 108.2 | — |
| [Panacea Biotec](https://app.pivotnow.in/stock/PANACEABIO) | ₹347.50 | ₹2,128 Cr | — | — |
| [Sakar Healthcare](https://app.pivotnow.in/stock/SAKAR) | ₹919.80 | ₹2,047 Cr | 67.3 | — |

## Questions and answers

### What is the share price of Indoco Remedies today?

Indoco Remedies (NSE: INDOCO) last closed at ₹230.30 on 21 Oct 2026. Its 52-week high is ₹291.00 and its 52-week low is ₹162.19.

### What is the market cap of Indoco Remedies?

Indoco Remedies' market capitalisation is ₹2,177 Cr (₹2,177 Cr) at the 19 Oct 2026 close, ranking 1122nd among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Indoco Remedies?

Return on equity was −10.1% in FY26 and return on capital employed was 1.2% in FY26 (consolidated figures).

### Is Indoco Remedies a debt-free company?

No. Indoco Remedies' debt-to-equity ratio was 1.1 in FY26, with total debt of ₹516 Cr.

### What were Indoco Remedies' latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), Indoco Remedies reported revenue of ₹466 Cr, +8.7% year on year, and net profit of ₹65 Cr.

### How has Indoco Remedies stock performed over the last year?

Indoco Remedies' share price has fallen 17.9% over the past year, −3.7% over three months and −7.0% over one month, to the 19 Oct 2026 close.

### What is the shareholding pattern of Indoco Remedies?

As of 30 Jun 2026: promoters 58.86%, foreign institutions 1.27%, domestic institutions 17.68%, non-institutions 22.04%.

### Who are Indoco Remedies' competitors?

The listed Pharma & Healthcare companies closest to Indoco Remedies by market cap are Dishman Carbogen Amcis, Vimta Labs, Medi Assist Healthcare Services, Sai Parenterals, Panacea Biotec and Sakar Healthcare.

### Is Indoco Remedies a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Indoco Remedies' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on INDOCO against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.